BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 5
• 6
• 7
• 8
• 9
• 12
• 13
• 14
• 15
• 16
• 19
• 20
• 21
• 22
• 23
• 26
• 27
• 28
• 29
• 30

• 

  Henry I. Miller

  Henry I. Miller, M.S., M.D., is a physician and molecular biologist. He is the Glenn Swogger Distinguished Fellow at the American Council on Science and Health. He was the founding director of the FDA’s Office of Biotechnology.
• 

  Mergers & acquisitions

  Broken Deals: 4 Pharma Assets Returned to Biotech This Year

  Not all licensing deals are successful. Here, BioSpace examines a few noteworthy assets that Big Pharma returned in the last 12 months.

  August 27, 2024

   · 

  5 min read

   · 

  Mollie Barnes
• 

  Pharmacy benefit managers

  Cigna to Remove AbbVie’s Humira From Formularies, Putting More Pressure on Blockbuster

  Mirroring fellow pharmacy benefit manager CVS Caremark, Cigna’s Express Scripts is taking Humira off its major commercial formularies starting next year and focusing on more affordable biosimilar options.

  August 27, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Job Trends

  Massachusetts’ Biopharma Jobs Grew at Slowed Rate in 2023: Report

  Massachusetts’ biopharma jobs increased 2.6% in 2023, according to the MassBio Industry Snapshot. Whether the state’s jobs grow in 2024 remains to be seen based on this year’s layoffs and seemingly slowed hiring based on BioSpace data.

  August 27, 2024

   · 

  5 min read

   · 

  Angela Gabriel
• 

  Lymphoma

  Regeneron Scores EU Lymphoma Approval for Bispecific Antibody Ordspono

  With the FDA’s rejection of Ordspono in March, Monday’s green light from the European Commission marks the first approval worldwide and the first regulatory victory for Regeneron’s bispecific antibody platform.

  August 27, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Drug pricing

  Medicare Coverage of Novo’s Semaglutide for CVD Could Cost $145B Annually: Study

  The number of patients who will be eligible for Novo Nordisk’s blockbuster GLP-1 under new Medicare Part D plan guidelines will vary depending on how cardiovascular disease is defined, according to researchers.

  August 27, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Obesity

  Lilly Looks to Expand Zepbound Supply by Offering Single-Dose Vials

  Through its online pharmacy LillyDirect, Eli Lilly announced Tuesday it will allow patients to purchase single-dose vials of Zepbound—without the autoinjector—at a 50% discount or more versus other incretin obesity treatments.

  August 27, 2024

   · 

  3 min read

   · 

  Tristan Manalac
• 

  Drug Development

  Oculis Closes Phase III Eye Drop Trial Due to Third-Party Administrative Error

  The company announced Tuesday that despite the error preventing the analysis of late-stage results, the FDA confirmed that data from other completed trials are sufficient to support an NDA submission in the first quarter of 2025.

  August 27, 2024

   · 

  1 min read

   · 

  Annalee Armstrong
• Press Releases

  Olympus Launches New POWERSEAL™ Sealer/Divider 5mm Devices, Extends Advanced Bipolar Surgical Energy Portfolio

  August 27, 2024

   · 

  6 min read
• Press Releases

  MPOX is Emerging as a Global Threat - NanoViricides Investigating MEURI Protocol for Using NV-387 to Treat MPOX

  August 27, 2024

   · 

  10 min read